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Background: Up to now, the different uptake pathways and the subsequent intracellular trafficking of plasmid DNA
have been largely explored. By contrast, the mode of internalization and the intracellular routing of an exogenous
mRNA in transfected cells are poorly investigated and remain to be elucidated. The bioavailability of internalized
mRNA depends on its intracellular routing and its potential accumulation in dynamic sorting sites for storage: stress
granules and processing bodies. This question is of particular significance when a secure transposon-based system
able to integrate a therapeutic transgene into the genome is used. Transposon vectors usually require two
components: a plasmid DNA, carrying the gene of interest, and a source of transposase allowing the integration of
the transgene. The principal drawback is the lasting presence of the transposase, which could remobilize the
transgene once it has been inserted. Our study focused on the pharmacokinetics of the transposition process
mediated by the piggyBac transposase mRNA transfection. Exogenous mRNA internalization and trafficking were
investigated towards a better apprehension and fine control of the piggyBac transposase bioavailability.
Results: The mRNA prototype designed in this study provides a very narrow expression window of transposase,
which allows high efficiency transposition with no cytotoxicity. Our data reveal that exogenous transposase mRNA
enters cells by clathrin and caveolae-mediated endocytosis, before finishing in late endosomes 3 h after
transfection. At this point, the mRNA is dissociated from its carrier and localized in stress granules, but not in
cytoplasmic processing bodies. Some weaker signals have been observed in stress granules at 18 h and 48 h
without causing prolonged production of the transposase. So, we designed an mRNA that is efficiently translated
with a peak of transposase production 18 h post-transfection without additional release of the molecule. This
confines the integration of the transgene in a very small time window.
Conclusion: Our results shed light on processes of exogenous mRNA trafficking, which are crucial to estimate the
mRNA bioavailability, and increase the biosafety of transgene integration mediated by transposition. This approach
provides a new way for limiting the transgene copy in the genome and their remobilization by mRNA engineering
and trafficking.
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The secure insertion of a therapeutic gene into a defective
cell is a major challenge for the gene-based treatment of
many diseases. Transposon-based systems are particularly
promising for use in integrating a gene of interest into the
genome, since they are considered to be less immunogenic
and to have a much larger cargo capacity than viral vectors,
while maintaining highly efficient transgene integration. To* Correspondence: florence.bonnin@univ-tours.fr
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reproduction in any medium, provided the ordate, few transposons have demonstrated their functional-
ity in mammalian cells and their usefulness for reshaping
the genome [1]. One that has, the piggyBac transposon,
which is derived from the cabbage looper moth
Trichoplusia ni, is mobile in many different species, in-
cluding human cells [2]. This transposon has a higher
cargo capacity [3] and is less susceptible to transposase
overproduction inhibition of transposition [4] than
Sleeping Beauty, another transposon widely used in
mammalian cells.
Transposon vectors require two components: a plas-
mid DNA (pDNA) carrying the gene of interest, and a. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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secure transposon system able to integrate stably at least
one copy of a therapeutic transgene per nuclear genome
appears to be necessary. Optimizing pDNA architecture
to ensure site directed integration of the transgene and
long-term expression through the use of insulator has
been described [5,6], but less has been characterized
about the source of transposase. Usually this source is a
pDNA carrying the transposase cDNA under the control
of a strong promoter. The principal drawback encoun-
tered using this strategy is the lasting presence of the
transposase due to persistence of the episomal pDNA
and/or the possible non-specific integration of the
transposase gene in the genome. This could remobilize
the transgene once it has been inserted, and thus lead to
genotoxicity. In an attempt to improve the biosafety of
gene integration, we chose to deliver the source of
transposase as a messenger RNA (mRNA), instead of the
commonly used pDNA. Besides the lability of mRNA,
the fact that it is not integrated into the genome elimi-
nates the risk of long-lasting side effects. mRNA is
attracting interest when only high levels and/or short-
term expression are required to achieve the desired ef-
fect. Consequently, mRNA is of particular relevance for
engineering secure transposon systems with limited
transposase expression. In this context, transgenesis pro-
tocols based on Sleeping Beauty or piggyBac transpos-
ition providing the transposase in the form of mRNA
have been validated in many eukaryotic species, includ-
ing mouse and rat models [7-9], and in cultured human
cells [10].
Despite the increasing use of mRNA as a promising al-
ternative to pDNA for several therapeutic purposes, few
transfection reagents have been developed for large
RNA, such as mRNA. Cationic lipids are the ones most
often used [11], since other reagents, including cationic
peptides [12] or cationic polymers [13], have demon-
strated poor efficiency in delivering mRNA, probably
due to differences in the uptake and intracellular traf-
ficking of mRNA formulations. So far, the various uptake
pathways and subsequent intracellular trafficking of
pDNA have been largely explored [14-16], whereas there
have been very few investigations of the delineation of
the intracellular fate of exogenous mRNA, which re-
mains to be elucidated.
Our study focused on the pharmacokinetics of the trans-
position process mediated by the piggyBac transposase
mRNA transfection of HeLa cells. We were interested in
assaying different commercial chemical reagents for mRNA
delivery. Then, in order to better apprehend the bioavail-
ability of the transfected transposase mRNA, both spatially
and temporally, we sought to shed light on exogenous
mRNA uptake and its subsequent intracellular trafficking
via endosomes and potential storage in Processing Bodies(P bodies) or Stress Granules (SG), which are cytoplasmic
foci involved in natural, endogenous mRNA regulation.
These aggregates can interact together and they constitute
kind of dynamic sorting sites for storage and/or turnover of
endogenous mRNA [17], where intracellular mRNA is
routed to sites of translation reinitiation, degradation or
storage [18].
Taken together, our results unveiling part of the pro-
cess of mRNA incorporation, release and intracellular
trafficking during transfection, would make it possible to
better apprehend the spatio-temporal bioavailability of
mRNA and improve the reliability of our transposon
vector.
Results and discussion
Efficiency of transfection reagents for mRNA delivery and
characterization of mRNA complexes
Electroporation and micro-injection are the most widely
used non-viral methods for delivering mRNA. Neverthe-
less, physical methods are both invasive and more cyto-
toxic than chemical methods, which also present the
advantage of condensing and thus protecting nucleic
acids from nucleases present in the cytoplasm; some-
thing which is of critical importance in the case of
mRNA delivery. The mRNA used throughout this study
was transcribed from the pCS2+ U5V5PBU3 plasmid in
the presence of an anti-reverse cap analogue (ARCA)
and then polyadenylated to enhance both the stability
and the translatability, as described elsewhere [13,19]
(Figure 1A). The ARCA allows capping with a modified
cap (m7(3′-O-methyl)G(5′)ppp(5′)G), in which one of
the 3′ OH groups is substituted with –OCH3. RNA
polymerases can only initiate transcription with the
remaining -OH group and thus synthesize RNA tran-
scripts capped exclusively in the correct orientation.
Our first aim was therefore to identify an efficient
commercially available transfection reagent for mRNA
transfection. For this purpose, we used different formu-
lations of transfection reagents, whether specially devel-
oped for mRNA transfection or not. Effective transfection
was confirmed by quantifying the protein produced by
Western-Blot analysis (V5PB Tp, Figure 1B) one day post-
transfection. All carriers led to the expression of mRNA,
but with clearly differing efficiencies. jetPEI™ was found to
be the most effective reagent for delivering mRNA in
HeLa cells, even though it had not been specifically
designed for mRNA transfection according to the Manu-
facturer. mRNA transfection using TransMessenger™ and
TransIT®mRNA, developed for mRNA delivery, produced
only 30% and 2% respectively, of the transposase produced
with jetPEI™, which corresponds to 3-fold and 50-fold
reductions of transfection efficiency in our conditions.
Consequently, PEI was used in the following experiments
to transfect mRNA in HeLa cells.
Figure 1 Efficiency of transfection reagents for mRNA delivery. (A) Diagram of a transposase vector plasmid and subsequent mRNA. The
transposase gene sequence fused with the V5 epitope tag sequence (V5PB) and surrounded by the UTR5′ (U5) and UTR3′ (U3) sequences of the
β-globin gene of the Xenopus laevis was cloned in the pCS2+ plasmid backbone to obtain the pCS2+ U5V5PBU3 construct. In vitro transcribed
mRNA (V5PB mRNA) harbors a cap analogue (ARCA) and a polyA tail. (B) Efficiency of various different transfection reagents for mRNA delivery
into HeLa cells. Cells were transfected with 200 ng of V5PB mRNA using jetPEI™ (N/P = 5), TransMessenger™ or TransIT®mRNA transfection
reagents. Transfection efficacy was checked following protein expression by Western-Blot analysis 24 h post-transfection using an antiV5-
Horseradish Peroxidase antibody to detect the tagged V5PB transposase (V5PB Tp). Protein quantification was normalized to the Menin
endogenous protein (ratios are indicated). Data are the average of 4 experiments. Mock is a negative control without mRNA transfected.
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order to better apprehend the behavior of such polyplexes
in vivo. First, the condensation of the mRNA transposase
(named V5PB) by PEI at various different N/P ratios was
analyzed by gel retardation assay and compared to pDNA/
PEI condensation (Figure 2). The N/P ratio refers to the
number of nitrogen residues of PEI per DNA phosphate,
it is a measure of the ionic balance of the complexes. It is
well established that during electrophoresis, complexes,
which are less negatively charged and heavier than free
pDNA or mRNA, are retained in the wells whereas un-
complexed nucleic acids can migrate into the gel [20]. As
shown in Figure 2A, the intensity of bands corresponding
to free, supercoiled pDNA migrating in the gel decreased
as the amount of PEI increased. At an N/P ratio of 5, all
the pDNA was complexed and retained in the wells. Simi-
lar experiments were performed with V5PB mRNA
(Figure 2B). Our results showed that an N/P ratio assmall as 0.75 was sufficient to totally condense the
mRNA, as no free mRNA migrated into the gel,
attesting that PEI has greater affinity for mRNA than
for pDNA, as described previously [12]. Even though
an N/P ratio of 0.75 was sufficient to complex all the
mRNA, the best transfection efficiency in cultured
cells was obtained using an N/P ratio of 5, suggesting
that free PEI is involved in the uptake and/or cytosolic
delivery of polyplexes (Additional file 1). Finally, the
size of V5PB mRNA/PEI polyplexes formed at an N/P
ratio of 5 was determined by dynamic light scattering.
The size distribution ranged from 140 to 300 nm, with
a mean size of 190 nm (Additional file 2). This was
consistent with results reported for pDNA polyplexes
and polyplexes made with other mRNA [21].
Our data show that linear PEI polyplexes used at an N/
P ratio of 5 are the most efficient formulation for promot-





















































Figure 2 Gel retardation assays. Electrophoretic migration of V5PB pDNA. (A) or mRNA (B) complexed with PEI at varying N/P ratios
ranging from 0 to 5. Complexes were prepared by mixing 1 μg of V5PB mRNA or pDNA with different amount of PEI according to the desired
ratio. Black arrowhead indicates supercoiled pDNA whereas grey arrowheads indicate different states of condensation of nicked pDNA.
Experiments have been done three times.
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ultaneously, an N/P ratio of 5 was used to transfect pDNA
and mRNA for the subsequent experiments.
Accessibility and functionality of the complexed mRNA
The accessibility of mRNA for translation when formu-
lated with PEI was assessed both in vitro and in cultured
cells. In vitro translation was performed using a cell-free
translation system based on rabbit reticulocyte lysate
coupled with Western-Blot detection (Figure 3A). The
efficiency of translation of free mRNA was compared to
that of mRNA/PEI complexes. A control consisting of
mRNA mixed with 150 mM NaCl excluded any poten-
tial salt effect during the in vitro translation step, as
translation of mRNA mixed with 150 mM NaCl was
equivalent to that with free mRNA. In contrast, the level
of translation obtained with mRNA/PEI particles, was 9.5-
fold lower than that obtained with free mRNA. These re-
sults suggest that condensation to PEI partially impedes,
but does not completely inhibit, translation. Partial trans-
lation due to remaining free mRNA is excluded since atthe N/P ratio of 5 used for this experiment, 100% of the
mRNA was found to be complexed. The time course of
translation into HeLa cells transfected with mRNA/PEI
polyplexes was studied at different times (Figure 3B).
Transposase production was detected as early as 3 h after
transfection, peaked at 18 h and then declined. After 48 h,
only traces were detected. This pattern may be explained
by the progressive degradation or storage of the V5PB
mRNA and/or protein in cytoplasmic foci. Indeed, quanti-
tative RT-PCR studies indicated a half-life of the PB
transposase mRNA of about 3 h, and western-blot analysis
after incubating the V5PB mRNA transfected cells with
cycloheximide, a known inhibitor of protein synthesis, in-
dicated a half-life of the PB transposase of 12 h (manu-
script in preparation). Overall, these data have shown for
the first time that the mRNA prototype designed and
characterized in this study provides a very short expres-
sion window of the piggyBac transposase.
Finally, the functionality of the transposase produced
from our mRNA was assayed in a transposition assay.
Briefly, HeLa cells were transfected with V5PB transposase








































Figure 3 mRNA/PEI availability for the in vitro and in vivo translation and functionality of V5PB transposase. (A) In vitro translation of
V5PB mRNA uncomplexed or complexed with PEI (N/P = 5). In vitro translation of mRNA alone (V5PB), in the presence of 150 mM NaCl (V5PB-
NaCl) or complexed with PEI (V5PB-NaCl + PEI). Proteins V5PB Tp and Menin were separated by SDS-PAGE before chemiluminescent detection
using an antiV5-Horseradish Peroxidase antibody. Mock is a negative control without mRNA. Experiments have been done in triplicate. (B) Time
course of cellular production of V5PB transposase in HeLa cells (V5PB Tp). Transposase expression was assayed at the indicated time points, and
monitored by Western-Blot experiments as described in (A). Mock: negative control (untransfected cells). Experiments have been done in
triplicate. (C) pBluescript plasmid (pBSK ITR5′NéoRITR3′) harboring the transposable element used in this study. This vector was composed of the
expression cassette encoding the neomycin phosphotransferase protein (NeoR) flanked by the inverted terminal repeats (ITR5′ and ITR3′), the
recognition sites of the piggyBac transposase necessary for the transposition step. (D) Transposition assays in HeLa cells. Cells were transfected
with the mRNA encoding the V5PB transposase and pBSK ITR5′NéoRITR3′. Transposition events involve the integration of the NeoR gene, and thus
the emergence of a resistance phenotype to G418. Positive cells were selected under antibiotic pressure for 15 days, and colonies were then
stained and counted. Mock is a negative control (without V5PB mRNA) corresponding to recombination events. The figures indicate the number
of colonies counted (mean value ± standard deviation of three independent experiments made in triplicate).
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cin resistance (pBSK ITR5′NeoRITR3′, Figure 3C). If
functional, the transposase will integrate the neomycin re-
sistance gene in the nuclear genome of cells, which
could be selected through antibiotic pressure. Transfectionof the V5PB mRNA led to a 6-fold increase in the colony
number compared to the mock control indicating that
transposase exhibits transposition activity (Figure 3D, right
panel, 1120 colonies). In the absence of transposase, 182
colonies were observed corresponding to recombination
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(Figure 3D, left panel). This is consistent with results
obtained by Wilber et al. with Sleeping Beauty mRNA
[10]. Consequently, the transfection of piggyBac mRNA
by PEI enabled in vitro and cellular translation of a func-
tional transposase, permitting transposition events to
occur with high efficiency.
The cytotoxicity of different mRNA/PEI and pDNA/PEI
polyplexes was evaluated 24 h and 48 h post-transfection
using a proliferation assay. The mRNA or pDNA of
piggyBac and green fluorescent protein (GFP) was tested
to exclude the possibility of any impact of the nucleic acid
sequence. No significant change of cell proliferation was
detected when cells were treated with the carrier alone,
suggesting that this carrier is safe and did not affect cell
viability under these conditions (Additional file 3). Simi-
larly, pDNA or mRNA condensed with PEI did not alter
cell proliferation. These findings suggested that mRNA or
pDNA complexed to PEI did not induce severe cell dam-
age in HeLa cells under our conditions.
Uptake pathways and subsequent intracellular trafficking
of mRNA polyplexes
As the intracellular fate is linked to the entry mechanism,
we studied the internalization routes of the mRNA
polyplexes, which had never previously been investigated.
We used confocal microscopy to reveal and quantify po-
tential colocalizations between a red fluorescent-labeled
V5PB mRNA and different markers of the endocytic path-
ways: caveolin-1 (caveolae), clathrin (clathrin-coated vesi-
cles) and Rab7 (late endosomes) labeled with green
fluorescence (Figure 4 and Table 1). Thirty minutes post-
transfection, mRNA was colocalized with caveolin-1, indi-
cating the involvement of the caveolae pathway in the
uptake of mRNA/PEI polyplexes by HeLa cells. By 2 h
post-treatment, slightly fewer complexes were visible
in this compartment, the mean number of yellow dots
dropped from 9.2 to 6.3 per cell (Table 1), suggesting
that about 32% of mRNA polyplexes had started to es-
cape from the caveolae vesicles into other compart-
ments (Figure 4A). Similarly, mRNA polyplexes were
found in clathrin vesicles, but fewer yellow dots were
visible at both 30 min and 2 h (mean number of 2.6
and 2.3 yellow dots per cell, respectively), suggesting
that the clathrin-mediated endocytosis is not the major
route or is a slower route than the caveolae pathway
for escaping from the early vesicles (Figure 4B). In
both these compartments, the mean number of red
dots is constant; they correspond to mRNA escaped
from the endocytosis vesicles. mRNA was found in late
endosomes as soon as 30 min post-transfection and
yellow dots appeared bigger and six time more abun-
dant after 2 h, in agreement with the endocytosis path-
way (Figure 4C). Similarly, the mean number of reddots per cell is increasing over time, suggesting that
mRNA is progressively released from late-endosomes.
These observations demonstrate that the uptake of
mRNA polyplexes of 200 nm in size at least involves
two major endosomal pathways including both the
caveolae and clathrin-coated pits in HeLa cells. This is
consistent with the particle size supported by these
endocytosis routes and the results obtained with
pDNA complexed with PEI in this cell type [22,23].
Recently, Lorenz et al. have concluded that a huge
amount of naked mRNA (20 μg) is taken up by a
caveolae-dependent pathway, and to a minor degree by
macropinocytosis, excluding any role of clathrin-coated
pits [24]. Moreover, Diken et al. showed a dominant role
of macropinocytosis in the uptake of naked RNA by im-
mature dendritic cells in vitro and in vivo [25]. In our
study, no fluorescent mRNA was observed inside the cells
in the absence of PEI when a small amount of mRNA was
used (0.5 μg), which is hardly internalized, as expected.
No red fluorescent mRNA was observed in nuclei. Once
internalized, some of the mRNA was directed to late
endosomes, as has been reported for pDNA polyplexes
[26]. At first glance, the mechanisms involved in mRNA
internalization do not seem to differ from those involved
in pDNA internalization in the early stages of transfection.
PEI is thought to facilitate the release of the polyplexes
into the cytoplasm thanks to a proton sponge effect,
which involves disruption of the late endosome through
its acidification, avoiding acidic lysosomes [27]. So, to
keep track of mRNA/carrier interactions during naviga-
tion through the cytosol, red fluorescent mRNA was
condensed with green fluorescent PEI and incubated
with HeLa cells. In Figure 5, an analysis carried out 3 h
post-transfection revealed the presence of: (i) cyto-
plasmic yellow dots corresponding to dual fluorescent
polyplexes, indicating that mRNA and the carrier were
still either compacted or localized together; (ii) green
spots related to PEI either alone or complexed to un-
labeled mRNA and (iii) red spots corresponding to
mRNA released from PEI. These data show that some of
the internalized mRNA was released from polyplexes 3 h
post-transfection, which corresponds to the beginning of
the transposase production (Figure 3B). It should be noted
that direct translation of mRNA/PEI complexes cannot be
ruled out, even though it may occur less efficiently than
naked mRNA. The quantification of the dots for each
color given in Table 2 indicates that 47% of the mRNA
still co-localized with PEI 3 h post-transfection (4.8 yellow
dots per cell versus 1.6 red dots per cell), suggesting
that mRNA release (18%) probably started at this ob-
served time. The mechanisms responsible for mRNA/
PEI dissociation, and where exactly this phenomenon

































Figure 4 (See legend on next page.)
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Figure 4 Uptake pathways of mRNA polyplexes by HeLa Cells. (A) Red fluorescent labeled V5PB mRNA compacted to PEI were administered
to HeLa cells. Clathrin detection was performed by immunofluorescence using an anti-clathrin primary antibody revealed with an Alexa-488
conjugated secondary antibody (green). Experiments have been done three times. (B and C) Red fluorescent-labeled V5PB mRNA was used to
transfect HeLa cells constitutively expressing green fluorescent caveolin-1 (B) or green fluorescent Rab7 proteins (C). Experiments have been
done three times. For all experiments, the route of the labeled polyplexes was observed at 30 min and 2 h post-transfection using confocal
microscopy. Yellow dots correspond to colocalization of red and green fluorescent spots. Insets shows enlargement of boxed areas with colors
separated. BF: Bright Field. Nuclei were stained in blue by lamin immunodetection (Caveolin and Rab7 experiments) or DRAQ5® (Clathrin
experiment). The images shown are representative Z-sections from three separated experiments.
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ends up once it has escaped from late endosomes,
whether it is still complexed with PEI or not. As the
above data suggest that some of our exogenous mRNA
could be available for translation in a condensed or free
state, we investigated whether the other fraction could
be stored in subcellular compartments, such as stress
granules (SG), which are sorting sites for endogenous
intracellular mRNA generated during cellular stress,
such as transfection [28], and processing bodies (P bod-
ies), which are involved in mRNA degradation [17,29].
Note that not all mRNA is intended to be degraded
within these foci, as translationally repressed mRNA can
also exit SG and P bodies to re-engage in translation [30].
Potential colocalizations of mRNA with SG and P bodies
were assessed 3 h, 18 h and 48 h post-transfection using
red fluorescent V5PB mRNA, and green-labeled SG and P
bodies markers (Figure 6).
As shown in Figure 6A, SG were present throughout
the cytoplasm 3 h post-transfection. A mean number of
3.1 merge spots per cell (Table 3) indicated that a part of
the exogenous mRNA was found in SG at this time. The
major part of mRNA did not colocalize with SG (18.4 red
dots per cell in average) when some mRNA was found
to be dissociated from PEI and translated. Fewer merge
dots were observed at 18 h and 48 h post-transfection (1.5






Caveolae (Caveolin-1) 30m 9.3 (±3.5) 9.2 (±2.5)
2h 8.5 (±5.3) 6.3 (±3.6)
Clathrin-coated vesicle
(Clathrin)
30min 4.4 (±1.7) 2.6 (±1.5)
2h 3.3 (±2.1) 2.3 (±1.5)
Late endosome (Rab-7) 30min 4.7 (±2) 1.1 (±0.4)
2h 7.2 (±2.6) 6 (±3.5)
Red fluorescent-labeled mRNA polyplexes were observed in three green
fluorescent endocytosis compartments 30 min and 3 h post-transfection.
Yellow dots are obtained when there is colocalization. Each value represents
the average number of detected dots for each color ± standard deviation per
whole cell. Three separate experiments were performed and at least 20 cells
were analysed using confocal microscopy and ImageJ software for
each condition.prolonged storage in these foci (Figure 6A and
Table 3). It is not known whether the mRNA directed
to SG is still functional. Nevertheless, it was found
that transposase mRNA sequestration at 3 h is not ef-
ficient enough to hinder the transposase production
and transposition (Figure 3). The mean number of red
dots per cell decreased over time, suggesting a degrad-
ation of the nucleic acids, which is consistent with
the half-life of the V5PB mRNA and the kinetic of
transposase expression (Table 3 and Figure 3B). We
showed here for the first time that transfected mRNA
could be directed to these specific granules, where it
could be stored for subsequent translation. SG could
be involved in the availability of exogenous mRNA by
influencing its cytoplasmic retention and/or its subse-
quent distribution. This could explain why, in spite
of a short half-life, traces of V5PB mRNA could be
detected for 2 days, probably due to its sustained re-
lease over time. However, the decrease in protein
expression from 18 h post-transfection despite the
storage of transposase mRNA in SG indicates that this
mechanism is not sufficient for prolonged protein pro-
duction. This argues in favor of transient transposase
expression and thus, stable transgene integration.
No colocalization with P bodies was detected 3 h, 18 h
and 48 h post-transfection despite observation of spots
corresponding to P bodies and to mRNA alone in the
cytoplasm. This indicates that no exogenous mRNA coa-
lesced in these foci at these times (Figure 6B). As for SG
observations, the mean number of red dots was decreas-
ing from 10.8 to 1.7 spots per cell over time, suggesting
mRNA degradation (Table 3). As theV5PB mRNA was
engineered for enhanced stability, the absence of P bodies
addressing elements such as AU-rich elements, 5′ stem
loops, premature translation termination codons, introns
or short poly(A) tails, could explain why it was not di-
rected to these foci [18]. Another explanation could also
be the residence time in such granules. Indeed, it has been
demonstrated that the transit time of mRNA in SG does
not exceed 60 s [31]. This rapid exchange may also occur
with P bodies, making it difficult to catch colocalization,
especially if such an event is rare. Similarly, the number of
colocalization events between mRNA and SG marker ob-




BF 3 h 
Figure 5 Dissociation of mRNA/PEI polyplexes in HeLa cells. Confocal microscopy images of HeLa cells incubated during 3 h with Alexa
Fluor® 546-labeled mRNA (red) condensed with jetPEI™-FluoF (green). Yellow dots correspond to merge signal. Green spots match with jetPEI™-
FluoF alone or complexed to unlabeled mRNA, and red spots correspond to dissociated mRNA from polyplexes. Experiments have been done
three times. Insets show enlargements of the boxed areas with the colors separated. BF: Bright Field. Nuclei are stained in blue by lamin
immunodetection. The images shown are representative Z-sections from three separated experiments. No red fluorescent mRNA was observed
in nuclei.
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to be 3 h, which is quite short considering the fact that
stabilizing sequences (cap, polyA tail and β-globin un-
translated regions (UTR)) had been added. As our mRNA
does not coalesce in P bodies, this could suggest that the
mechanisms responsible for exogenous mRNA degrad-
ation probably do not depend on the decapping pathway.
Conclusions
Taking together, results reported in this study shed new
light on the bioavailability of the piggyBac transposase,
and the security of the transposition process by studying
exogenous mRNA transfection and its underlying intra-
cellular trafficking and fate. This offers several starting
points of special relevance for any study requiring
mRNA delivery. A schematic model based on our results
and on observations in the literature is proposed in
Figure 7.
In the transposition process, in vitro transcribed
mRNA delivery and accessibility are satisfactory, as only
short-term expression is required. Moreover, mRNA la-
bility property due to rapid degradation by ubiquitous
RNases and lack of integration into the genome elimi-
nates the risk of long-lasting side effects and makes it
clinically safer than pDNA for transposase expression.









1.9 (±1.7) 18% 3.6 (±1.8) 35% 4.8 (±3.1) 47%
Dissociation of red fluorescent-labeled mRNA from green fluorescent PEI
polyplexes 3 h post-transfection. Yellow dots are obtained when there is
colocalization. Each value represents the average number of detected dots for
each color ± standard deviation per whole cell. Three separate experiments
were performed and at least 20 cells were analysed using confocal microscopy
and ImageJ software for each condition.and the generation of induced pluripotent stem cells,
greater mRNA availability would be required. mRNA
could be engineered as needed to affect its expression
and stability by using optimized cap analogue and poly
(A) tails of variable length or by adding 3′UTR of
various origins [13,19,32]. Finally, the sequence of the
mRNA could be modulated to limit addressing to
RNA granules, and produce mRNA “resistant” to SG
or P bodies [18].
A lot still needs to be done to improve mRNA uptake
and expression, but the increased knowledge that has
been acquired these recent decades about pDNA deliv-
ery could be fully exploited during the first steps of
mRNA transfection. To conclude, exact knowledge of
spatial and temporal control of mRNA bioavailability is
crucial to achieve improved biosafety of transposon vec-
tors, which is a pre-requisite for the purpose of secure
ex vivo gene and cell therapies, but it will also provide
the basis for improving transfection efficiency and for
designing novel devices for the cytosolic delivery of
mRNA, and be beneficial for the development of many




The construct designated V5PB pDNA (6.4 kbp) was
made as follows: the 3′UTR fragment of the Xenopus
laevis β-globin gene (designated U3, 317 bp) was re-
moved from pBSSK/SB10 (kindly supplied by Dr.Z. Ivics,
Max Delbrück Center, Germany), and inserted into
pCS2+ already containing the 5′UTR (designated U5)
(Invitrogen/Life Technologies, Paisley, UK). The piggyBac
transposase fused with the V5 epitope tag (V5PB) (2067 bp)
[GenBank accession number: EF587698, [33] was synthe-
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Figure 6 (See legend on next page.)
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Figure 6 mRNA localization in subcellular foci. HeLa cells were observed using confocal microscopy 3 h, 18 h and 48 h post-transfection with
500 ng of red fluorescent-labeled V5PB mRNA polyplexes. Experiments have been done three times. GE-1/Hedls (P bodies marker) (A) and the
eukaryotic initiation factor-3 eIF3η (Stress Granules marker, SGs) (B) were immunodetected using specific green fluorescent secondary antibodies.
Insets show enlargements of the boxed areas with separated colors. Arrows indicate representative foci. The primary antibody directed against
the nuclear p70 S6 kinase protein reveals P bodies foci due to cross-reactivity with GE-1/Hedls, and exhibits nuclear staining due to p70 S6 kinase
protein detection. Nuclei were stained in green (A) or blue by DRAQ5® (B). BF: Bright Field. The images shown are representative Z-section from
three separated experiments. No re5d fluorescent mRNA was observed in nuclei.
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negative control plasmid designated GFP pDNA (5.1 kbp)
was built by ligation of the green fluorescent protein coding
sequence (800 bp) between the UTRs of the pCS2 +U5U3
construct.
Donor plasmid
pBSK- ITR5′-Neo-ITR3′ (5.2 kbp) was generated by
introducing the piggyBac 5′ and 3′ Inverted Terminal
Repeats (ITRs, 717 bp) into the pBluescript SK- plasmid
(Agilent Technologies, Santa-Clara CA, USA). The neo-
mycin phosphotransferase gene (1515 bp) under control
of the SV40 promoter was then inserted between the
ITRs.
In vitro mRNA synthesis
V5PB pDNA or GFP pDNA templates for mRNA syn-
thesis were linearized by NotI digestion and followed by
proteinase K treatment and phenol/chloroform extrac-
tion. In vitro transcription of capped mRNA was
performed onto the linear templates according to the
Manufacturer′s instructions using the MEGA Script SP6
kit (Ambion/Applied Biosystems, Austin TX, USA)
combined with the ARCA (Anti-Reverse Cap Analog
kit, Ambion). The resulting mRNAs were therefore
polyadenylated using a Poly(A) Tailing kit (Ambion),
and finally suspended in nuclease-free water after lith-
ium chloride precipitation. The quality was checked by






Stress granules 3h 18.4 (±5.9) 3.1 (±1.8)
18h 6 (±2.4) 1.5 (±0.8)
48h 2.6 (±0.9) 1.5 (±0.5)
P bodies 3h 10.8 (±4.6) 0
18h 8 (±2.8) 0
48h 1.7 (±0.7) 0
Distribution of red fluorescent-labeled mRNA in green subcellular foci 3 h,
18 h and 48 h post-transfection. Yellow dots are obtained when there is
collocation. Each value represents the average number of detected dots for
each color ± standard deviation per whole cell. Three separate experiments
were performed and at least 20 cells were analysed using confocal microscopy
and ImageJ software for each condition.concentration was determined by measuring the ab-
sorbance at 260 nm before storage at -80°C. piggyBac
and GFP mRNAs are named V5PB mRNA (2.5 kb) and
GFP mRNA (1.3 kb) respectively. Fluorescent labeled
V5PB mRNA was produced using 2 μL of ChromaTide®
Alexa Fluor® 546-14-UTP (red fluorescence, λEx: 550 nm,
λEm: 570 nm, Invitrogen) during an in vitro transcription
reaction.
Cell lines and culture
HeLa cells (ATCC CCL-2) were cultured in 75 cm2
flasks (PAA Laboratories, Pasching, Austria) in DMEM
supplemented with 10% fetal bovine serum (PAA La-
boratories), 275 units of penicillin, and 275 units of
streptomycin at 37°C in a humidified 5% CO2-containing
atmosphere. HeLa-caveolin-1-eGFP and Hela-Rab7-eGFP,
which are clones that constitutively express caveolin-1 or
Rab7 fused with eGFP, were cultured in the same medium,
but in the presence of 100 μg/mL of gentamicin.
Nucleic Acid (NA) transfection
Cells were plated at a density of 1.105 cells per well in
24-well plates and grown for 24 h to 80% confluence.
Transfections using TransMessenger™ (Qiagen, Hilden,
Germany) or TransIT®mRNA (Mirus Bio, Madison WI,
USA) were performed following the manufacturer’s in-
structions. Transfections using jetPEI™ or fluorescein-
labeled jetPEI™-FluoF (Polyplus Transfection, Illkirch,
France) were performed at an N/P ratio of 5 in Opti-
MEM (Invitrogen) following the Manufacturer’s proto-
col. When mRNA and pDNA were co-transfected,
complexes were formed separately with the transfec-
tion reagent to avoid mRNA degradation due to RN-
ases potentially present in the pDNA preparation.
Cells were then incubated at 37°C for 30 min to 48 h,
depending on the experiment.
Gel retardation assay of mRNA complexes
One microgram of transposase mRNA and the appropri-
ate amount of the jetPEI™ were supplemented with 150
mM sodium chloride to 25 μL and vortexed. The diluted
jetPEI™ was added to the mRNA solution at different
N/P ratios and vortexed. After 30 min of incubation at
room temperature, the complex solution (50 μL) was
mixed with 5 μL loading buffer and applied to a 0.8%
Figure 7 Model of the trafficking of exogenous mRNA. V5PB mRNA polyplexes could be both internalized by clathrin- and caveolin-mediated
endocytosis 30 min after the cell treatment. Polyplexes in clathrin-coated vesicles are then directed to late endosomes 2 h post-transfection. One
fraction of the mRNA polyplexes engulfed by caveolae is also targeted to late endosomes, whereas another fraction, trapped in caveosomes, is
assumed to end up in other cytoplasmic compartments, such as the endoplasmic reticulum (ER) or the Golgi apparatus. mRNA polyplexes escape
from the late endosome before its fusion with lysosomal vesicles thanks to the PEI proton sponge effect 3 h after cell transfection. PEI and mRNA
dissociate from each other. Some of the V5PB mRNA can reach the translational machinery (polysomes) for protein synthesis, as demonstrated by
transposase expression, whereas other fractions may be directed to RNA stress granules for transient storage.
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Electrophoresis was performed with a current of 90 V for
1 h in autoclaved TAE as running buffer and mRNA
localization was visualized by ultraviolet transillumination.
Western-blot
Cells were transfected using 200 ng of V5PB mRNA and
a total protein extraction was performed 24 h post-
transfection with 500 μL of extraction buffer containing
0.5% SDS, 100 mM NaCl, 10 mM ß-Mercaptoethanol
and 1X protease inhibitor. Cell lysate was sonicated
twice for 10 s, heated for 5 min to 95°C, and centrifuged
for 5 min at 10,000 rpm at room temperature. 15 μg of
protein extract supernatant were loaded per lane in a
4-10% gradient SDS-PAGE gel. The gel was transferred
to a Hybond-ECL™ membrane (GE Healthcare, Little
Chalfont, UK), and the membrane was blocked with5% non-fat dry milk dissolved in PBS-Tween20 0.05%
for 1 h at room temperature. It was then incubated over-
night with a mouse anti-V5 HRP antibody (Invitrogen) di-
luted 1/5000. Specific piggyBac transposase (known as
V5PB Tp) bands were detected using an ECL™ Western-
Blot Analysis System (GE Healthcare) and an LAS-4000
apparatus (Fujifilm, Tokyo, Japan). Protein quantification
was performed with the MultiGauge 4.0 software, and
normalized to an endogenous protein: Menin, detected
using a home-made antibody.
In vitro translation of mRNA transcripts
In vitro translation of in vitro transcribed mRNA was
performed according to the Manufacturer’s instructions
using a nuclease-treated Rabbit Reticulocyte Lysate
System (Promega, Madison WI, USA). Briefly, 2 μg
of transposase mRNA, either free or condensed by
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and translation products were separated by SDS-PAGE
before chemiluminescent detection of the V5 tagged
transposase using an anti-V5 horseradish peroxidase
antibody as described above.
Transposition assay
Cells were co-transfected with 200 ng of V5PB mRNA
and with equal amounts of donor plasmid to produce a
1:1 ratio. Two days after transfection, cells were trans-
ferred to 100 mm plates followed by G418 selection (800
μg/mL, PAA Laboratories) for 15 days. Colonies were
fixed and stained with 70% ethanol-0.5% methylene blue
for counting. Only colonies >0.5 mm in diameter were
counted.
Immunofluorescence and confocal laser scanning
microscopy
HeLa cells were seeded at 6.104 cells per well in 24-well
plates containing glass cover slips. On the next day they
were transfected with 500 ng of red fluorescent-labeled
mRNA. Cells were fixed with 4% p-formaldehyde, and
cover slips were mounted on slides using Vectashield
mounting medium (Vector Laboratories, Burlingame
CA, USA) for confocal microscopy observation.
mRNA/PEI co-localization. Cells were transfected with
mRNA complexed with jetPEI™-FluoF, a green fluorescent-
labeled jetPEI™ at an N/P ratio of 5. Cells were fixed at 30
min or 3 h post transfection and mounted.
mRNA endocytosis. HeLa-caveolin-1-eGFP and Hela-
Rab7-eGFP were transfected with V5PB mRNA complexed
with jetPEI™ (N/P of 5). 30 min or 2 h post-transfection,
cover slips were fixed and mounted. For experiments in-
volving the clathrin pathway, cells were fixed and perme-
abilized for 15 min with 0.5% Triton-X 100 in PBS. Mouse
anti-Clathrin HC primary antibody (Santa Cruz Biotech-
nology, Santa Cruz CA, USA, sc-271252) was then added
for 1 h at room temperature, followed by a 45 min incuba-
tion with Alexa Fluor® 488 goat anti-mouse IgG (H + L)
secondary antibody (Invitrogen) before mounting. Primary
and secondary antibodies were diluted in 1% BSA-PBS
blocking solution.
mRNA and stress granules or processing bodies
colocalizations. HeLa cells were transfected as de-
scribed above. Three hours, 18 h or 48 h post-transfection,
cells were treated with 5 mg/mL digitonin for 5 min, fixed
and permeabilized. GE-1/hedls and eIF3η markers were
chosen to detect processing bodies and stress granules, re-
spectively [28]. The GE-1/hedls marker can be detected
using an anti-p70 S6 kinase monoclonal antibody, which
exhibits strong cross-reactivity towards GE-1/hedls pro-
teins situated in cytoplasmic P bodies and p70 S6 kinase
located in the nucleus [28]. Mouse anti-p70 S6 kinase pri-
mary antibody (Santa Cruz Biotechnology, sc-8418) forthe detection of P bodies, or goat anti-eIF3η primary anti-
body (Santa Cruz Biotechnology, sc-16377) for the de-
tection of stress granules, was added for 1 h at room
temperature. Cells were then incubated with Alexa Fluor®
488 goat anti-mouse IgG (H + L) (Invitrogen) or donkey
anti-goat IgG-FITC (Santa Cruz Biotechnology, sc-2024)
secondary antibodies before mounting. Primary and sec-
ondary antibodies were diluted in 1% BSA-PBS blocking
solution.
Nuclei were stained in blue using DRAQ5® (5 μM, 30
min, Cell Signaling Technology, Danvers MA, USA) for
experiments with clathrin and stress granules. Nuclei
were stained in blue using a Goat anti-Lamin A/C
(N-18) sc-6215 primary antibody (Santa Cruz Bio-
technology), coupled with donkey anti-goat IgG-
PerCP-Cy5.5: sc-45102 (Santa Cruz Biotechnology)
for experiments with caveolin-1, Rab7 and jetPEI™-
FluoF. Nuclei were stained green due to cross-reactivity of
the primary antibody with the nuclear p70 S6 kinase in
the experiments with P bodies. All antibodies used showed
successful specific isotype controls since treating cells with
the secondary antibodies alone revealed no signal.
Slides were analyzed using an LSM 510 META scan-
ning device coupled to an Axiovert 200 microscope
(Carl Zeiss, Oberkochen, Germany). Each experiment
was performed three times, and representative images
were obtained from randomly-selected areas, all ana-
lyzed using Z-sectioning. Images were processed using
the routine software of the LSM 510 and ImageJ.Additional files
Additional file 1: N/P ratio alternative. Method: 1.105 HeLa cells were
transfected with 500 ng of GFP mRNA using PEI during 3 h. After
transfection incubation, cells were washed three times with PBS before
microscopy observation using Nikon Eclipse Ti and NIS-Elements
software. Figure legend: Cells are transfected with 500 ng of GFP mRNA
using PEI at N/P ratio of 1 (A); 3 (B); 4 (C) or 5 (D) and protein expression
is analyzed by epifluorescence microscopy with the x10 optical. Higher
transfection efficiency is obtained using a N/P ratio of 5.
Additional file 2: Determination of the size of the complexes.
Method: V5PB mRNA/PEI complexes were prepared in a final volume of
1.4 mL of 150 mM NaCl using 14 μg of transposase mRNA, and the
appropriate amount of jetPEI™ (N/P ratio of 5). The average particle size
of the polyplexes was determined twice by dynamic light scattering
using the Zetasizer 3000 (Malvern Instruments, Malvern, UK) with the
following specifications: automatic sampling time, 10 measurements per
sample, medium viscosity 0.89 cP, refractive index medium 1.33,
temperature 25°C. Figure legend: Determination of the size of PEI-V5PB
mRNA conjugates at an N/P ratio of 5. (A) Particles size, intensity, volume
and number were determined by dynamic light scattering after 30 min
of condensation. (B) Peaks analyses by intensity, volume and number.
Data show two peaks with an average size of approximately 190 nm and
2150 nm. The first peak correspond to mRNA complexed with PEI, the
second peak correspond to mRNA alone (uncomplexed or released over
time due to the long time needed for data acquisition).
Additional file 3: Cell proliferation assay. Method: Cell proliferation
was evaluated 24 h and 48 h post-transfection of 1.104 cells by
performing an MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
Bire et al. BMC Biotechnology 2013, 13:75 Page 14 of 15
http://www.biomedcentral.com/1472-6750/13/75bromide) assay according to manufacturer’s instructions (CellTiter96®
Non-Radioactive Proliferation assay, Promega). Briefly, the culture medium
was replaced by 100 μL of fresh medium supplemented with 15 μL Dye
solution. After 4 h incubation at 37°C, 100 μL Solubilization/Stop solution
were added followed by further 1 h incubation at 37°C. Sample
absorbance and background absorbance were measured at 595 nm and
at 650 nm with a spectrophotometer (Biophotometer Plus, Eppendorf,
Hamburg, Germany). The cell viability was calculated by subtracting the
absorption at 650 nm (background absorbance) from the absorption at
595 nm. The viability of non-transfected cells was set as 100% as a
standard. Figure legend: Viability of HeLa cells after transfection with PEI/
mRNA or pDNA. Cells were transfected using PEI (N/P = 5) alone or with
200 ng of V5PB or GFP mRNA or pDNA. One or two days post transfection,
cell viability was assayed using the CellTiter96® Non-Radioactive Proliferation
MTT assay. Values obtained for cells without treatment (mock) were set to
100%. Values represent the means ± SD (n = 4).
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